Hill-Rom (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Hill-Rom has outperformed the broader industry in the past year. Of late, the company has been seeing solid year-over-year increase in revenues on strong international growth primarily banking on the 'One Hill-Rom' approach. The company is focusing on product innovation, the latest one being Connex Cardio ECG. Hill-Rom has updated its 2020 long-range financial objectives and outlook considering gains from the new tax reform. Hill-Rom now expects to drive adjusted earnings by 12-14% on a compound annual basis through 2020, compared with the previous guidance of 10-12%. Moreover, an improvement in gross and adjusted operating margin buoys optimism.However, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.”
Other equities analysts also recently issued research reports about the stock. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Needham & Company LLC reissued a “buy” rating on shares of Hill-Rom in a research note on Friday, January 26th. KeyCorp reaffirmed a “buy” rating and issued a $97.00 price target on shares of Hill-Rom in a report on Thursday, January 18th. Barclays reaffirmed a “buy” rating and issued a $100.00 price target on shares of Hill-Rom in a report on Wednesday, January 10th. Finally, Morgan Stanley lowered shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 2nd. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $93.89.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings data on Friday, January 26th. The medical technology company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.13. The company had revenue of $669.70 million during the quarter, compared to the consensus estimate of $670.00 million. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. Hill-Rom’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.75 earnings per share. sell-side analysts expect that Hill-Rom will post 4.62 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its holdings in Hill-Rom by 5.6% in the fourth quarter. Amalgamated Bank now owns 13,796 shares of the medical technology company’s stock worth $1,163,000 after purchasing an additional 729 shares during the last quarter. Liberty Mutual Group Asset Management Inc. grew its holdings in shares of Hill-Rom by 5.4% during the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 16,724 shares of the medical technology company’s stock valued at $1,410,000 after buying an additional 853 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Hill-Rom by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,611 shares of the medical technology company’s stock valued at $711,000 after buying an additional 877 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Hill-Rom by 27.0% during the fourth quarter. LPL Financial LLC now owns 4,660 shares of the medical technology company’s stock valued at $394,000 after buying an additional 991 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Hill-Rom by 52.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,357 shares of the medical technology company’s stock valued at $283,000 after buying an additional 1,156 shares during the last quarter. 82.50% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Downgrades Hill-Rom (HRC) to Hold” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3335415/zacks-investment-research-downgrades-hill-rom-hrc-to-hold.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.